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Individualized therapies are popular current concepts in oncology and first steps towards 3 
stratified medicine have now been taken in neurooncology through implementation of 4 
stratified therapeutic approaches. Knowledge about the molecular basis of brain tumors has 5 
expanded greatly in recent years and a few molecular alterations are studied routinely because 6 
of their clinical relevance. However, no single targeted agent has yet been fully approved for 7 
the treatment of glial brain tumors. In this review, we argue that multidisciplinary and 8 
integrated approaches are essential for translational research and the development of new 9 
treatments for patients with malignant gliomas, and we present a conceptual framework in 10 
which to place the components of such an interdisciplinary approach. We believe that this 11 
ambitious goal can be best realized through strong cooperation of brain tumor centers with 12 
local hospitals and physicians; such an approach enables close dialogue between expert 13 
subspecialty clinicians and local therapists to consider all aspects of this increasingly complex 14 

















Advances in the understanding of tumor biology and the availability of more sophisticated 3 
technical tools for molecular genetic analyses in recent years has led to an exponential 4 
increase in the knowledge of genetic alterations linked to gliomagenesis [117, 118]. While 5 
these findings have widened our understanding of the underlying biology of the disease, they 6 
have also increased our awareness of its complexity. For example, intertumoral and 7 
intratumoral heterogeneity may influence outcome and treatment response; the vascular niche, 8 
the (hypoxic) stem cell niche or infiltrating glioma cells (to name but a few) all have their 9 
own molecular characteristics [76, 116]; and molecular changes occur on multiple regulatory 10 
levels (genomic, transcriptional, epigenetic) and are interconnected, such as miRNAs may 11 
control sophisticated signaling networks [83, 85, 122]. Taken together, these different facets 12 
of the disease have an enormous potential to influence diagnostic decisions and to stimulate 13 
the development of novel therapies.  14 
 15 
At the same time, the molecular changes that have been translated into a clinically meaningful 16 
context are not many and no targeted agent has yet been fully approved for the teatment of 17 
gliomas. A few molecular alterations such as MGMT methylation, deletions on chromosome 18 
arms 1p/19q and IDH1/2 mutations have been successfully linked to predictive and/or 19 
prognostic information [114, 115]. However, although frequently evaluated, their use for 20 
clinical decision-making is not yet widespread in the general community [56]. In addition, 21 
novel genetically defined subgroups within histologically homogenous tumor entities and 22 
global molecular signatures with prognostically relevant content have been identified [120]. 23 
Further, we are on the verge of understanding the molecular correlates of chemotherapy 24 
resistance. These are first steps emphasizing the transfer of basic research insights into 25 
clinically relevant applications. Finally, the interconnection of tissue-based information with 26 
data from imaging methods such as magnetic resonance techniques and positron emission 27 
tomography plays increasing roles in diagnostics and therapeutics [35]. Here, all types of 28 
information converge to establish an optimized treatment strategy. 29 
 30 
With a multitude of molecular alterations now known through high-throughput profiling 31 
studies [22], one of the major future challenges will be the determination of how those 32 
changes might be exploited to our patients’ benefit. While we are far from providing final 33 
answers to this important challenge, we here review approaches that connect molecular with 34 
4 
 
histopathological and clinical as well as imaging information. We further believe that such 1 
approaches can be best realized in an environment where clinicians and basic scientists work 2 
closely together to illuminate the many aspects of this increasingly complex disease and 3 
where they connect to local hospitals and physicians to bring optimal treatment to patients. As 4 
such we argue that current optimum neuro-oncology treatment and research must be 5 
multidisciplinary and interdisciplinary. In the following commentary, we provide a series of 6 




Argument #1:  Diagnosis is necessarily complex and requires expert neuropathologists 11 
 12 
 #1a: Histology and molecular pathology are increasingly interconnected 13 
Since its first edition in 1979, the WHO classification of tumors of the central nervous system 14 
has been developed periodically by correlating histopathological findings with clinical 15 
information, primarily survival data. To date, the WHO brain tumor classification (most 16 
recently updated in 2007) is still based on histological and immunohistochemical findings 17 
[78]. However, given the emerging knowledge of the molecular basis of brain tumors, 18 
molecular analyses will likely be increasingly incorporated in future revisions of the 19 
classification [77]. A few examples in this direction are as follows (also compare Table 1): 20 
 21 
 Molecular subtypes of glioblastomas 22 
Histologically defined glioblastoma represents a molecularly diverse set of entities. For 23 
example primary (de novo) and secondary (derived from a lower-grade precursor 24 
lesion) glioblastoma have long been distinguished from one another [68, 93]. While 25 
histologically indistinguishable, these tumors exhibit divergent molecular profiles [74, 26 
93, 114]. Data from large-scale profiling approaches (for details see below) identified 27 
even higher numbers of molecularly defined glioblastoma subgroups with clinical 28 
relevance [99, 140]. For molecular-driven therapies this additional information would 29 
have to be incorporated into the overall tissue diagnosis and passed from the 30 
neuropathologist to the clinician; to do so in many instances, particularly in the setting 31 





 Molecular differential diagnoses of astrocytic gliomas  1 
Molecular genetics may be beneficial in stratifying astrocytomas with ambiguous 2 
histological features into groups that are more likely to behave similarly in response to 3 
treatment. One example in this respect would be the case of high-grade glial neoplasms 4 
that appear highly pleomorphic but in which histological criteria for the diagnosis of 5 
glioblastoma are not completely fulfilled and uncertainty remains whether this may be 6 
merely due to incomplete sampling. In such cases, the presence of a mutant IDH might 7 
raise caution for the diagnosis of a WHO grade IV lesion, while the IDH wildtype 8 
situation may support the possibility that the tumor is likely to behave in an 9 
unfavorable, glioblastoma-like fashion [4, 47, 59]. As IDH mutations are tumor-specific 10 
alterations that do not occur in non-neoplastic cell populations, they may also aid in the 11 
sometimes subtle differential diagnosis between reactive astrogliosis or the infiltrative 12 
rim of a low-grade glioma containing only isolated invading tumor cells [21, 121]. 13 
Other molecular alterations may support the sometimes difficult differential diagnosis 14 
between infiltrating astrocytomas and astrocytic tumors with a more circumscribed 15 
growth pattern [78, 119]. As such, BRAF gene alterations (and in particular a BRAF-16 
KIAA1549 fusion gene) might help to differentiate pilocytic astrocytomas from 17 
diffusely infiltrating low-grade astrocytomas (the latter in turn show common IDH gene 18 
mutations) [5, 64, 65]. BRAF V600E mutations may also provide support for the 19 
diagnosis of an (anaplastic) pleomorphic xanthoastrocytoma over that of a glioblastoma 20 
[125, 143]. 21 
 22 
 Molecular diagnostics of oligodendroglial neoplasms 23 
Because oligodendroglial tumors follow a better clinical course and because recent data 24 
has shown that 1p/19q-codeleted oligodendroglial tumors should be treated with 25 
combined radiochemotherapy, their precise histological identification is of major 26 
clinical importance [20, 112, 138]. However, the histological features of 27 
oligodendroglial differentiation are prone to marked interobserver variability [71, 135]. 28 
In such cases, the integration of histological and molecular information becomes 29 
important. While it is still a matter of debate if the presence of 1p/19q deletions should 30 
define oligodendroglioma, these prognostically favorable molecular alterations are very 31 
common in oligodendroglial tumors (up to 80% of oligodendrogliomas and 30-50% of 32 
oligoastrocytomas) [18, 19, 20, 136, 138, 148]. Thus, in cases with questionable 33 
oligodendroglial histology, 1p/19q testing can help to identify those patients that follow 34 
6 
 
a better clinical course. In terms of therapies for oligoastrocytoma, this combination of 1 
histological and molecular information is also important because these tumors do not 2 
form a homogeneous group of neoplasms and histology alone does not sufficiently 3 
reveal their nature. Only molecular analysis can segregate lesions with the molecular 4 
characteristics of an oligodendroglioma (1p/19q codeletion) from those that more 5 
resemble a diffusely infiltrating astrocytic neoplasm (TP53 mutation, 17p loss, 6 
chromosome 7 gain) [81, 88]. 7 
 8 
These three examples emphasize that a combination of histology, immunohistochemistry and 9 
molecular genetics is required for diagnostic approaches. The combination is more than the 10 
mere synopsis of the information obtained from the different investigative levels. Accurate 11 
brain tumor classification has to weigh histological and molecular information carefully in 12 
light of the therapeutic options available. In many instances, brain tumor diagnostics is not 13 
straightforward and requires a high degree of expertise and knowledge about the clinical 14 
consequences of a specific differential diagnosis.  15 
 16 
The diagnosis of rare tumor entities also carries challenges. Tumors such as angiocentric 17 
glioma, papillary tumors of the pineal region, papillary glioneuronal tumor and rosette-18 
forming glionueronal tumor of the fourth ventricle have only recently been added to the WHO 19 
classification [78]. Most of these tumors are rare and awareness of their existence and 20 
differential diagnosis is more likely in neuropathological institutions where such tumors are 21 
seen in greater numbers. Once identified, the lack of extensive published experience treating 22 
such tumors means that the clinical implications of such diagnoses have to be individualized. 23 
Thus, although the details of these rare entities is beyond the scope of this review, their rarity 24 
makes them as important as common entities in terms of this conceptual framework of 25 
interdisciplinary clinical approaches.  26 
 27 
 28 
#1b: Proper molecular diagnostics requires dual molecular and histopathological expertise  29 
Tissue expertise is a required starting point for state-of-the-art molecular diagnostics. The 30 
proper work-up of tissue specimens can be complex and requires the expertise of a 31 
neuropathologist. For example, because most molecular assays are tumor-lysate based 32 
approaches, histopathological characterization to identify representative tumor tissue is 33 
essential prior to homogenization. In addition, tumor cell content should be carefully 34 
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controlled for since some assays (such as MGMT methylation testing, which requires cut-off 1 
values and reports percentages) depend on a sufficient tumor cell content within the sample 2 
[115]. In this context, it is important to point out that nearly all molecular tests have not yet 3 
been validated independently, leading to discrepancies between laboratories.  4 
For example, several methylation assays have been described for MGMT promoter 5 
methylation testing. In addition to the methylation-specific PCR assay [52], combined 6 
bisulfite restriction analysis, methylation specific sequencing and pyrosequencing as well 7 
restriction enzyme-based approaches (that do not require bisulfite conversion, e.g. methyl-8 
QESD [10]) are in use. For the assays, primers are not standardized between laboratories so 9 
that different regions of the gene promotor and a different number of CG sites are being 10 
assessed. In this regard, it is unclear which methylation site corresponds best to clinical 11 
response [27]. Such pitfalls handicap the comparability of testing results between individual 12 
laboratories and make definition of clear cut-off levels questionable [115]. For these reasons, 13 
the establishment of a consensus testing method that enables interlaboratory testing would be 14 
desirable. New directions could involve combined assessment of gene methylation with 15 
protein expression [72, 146]. Such consensus would require inter-institutional agreements, 16 
perhaps through the involvement of national and international trial organizations. 17 
Similar quality and comparability aspects have to be taken into consideration for assays of 1p 18 
and 19q deletions where PCR-based and FISH methods coexist and deletions of specific 19 
regions may bear an inverse prognostic meaning [41, 139]. All these natural limitations of the 20 
methods have to be kept in mind and, in combination with the histological findings, have to 21 
be adequately communicated to the clinician. 22 
 23 
 24 
#1c: Correct diagnosis and tissue processing is the basis for interpretation of research 25 
results. 26 
Another important aspect that requires the input of neuropathologists is brain tumor banking. 27 
Tumor banking stimulates basic, translational and clinical research aspects in many ways. The 28 
collection of prospective cohorts of clinically well-annotated tumor samples supplies a unique 29 
resource for basic researchers and clinicians by combining molecular and histopathological 30 
with clinical and prognostic information [54, 139]. As a consequence, tissue banks in brain 31 
tumor centers are a common resource usually goverened by a steering board that involves all 32 
disciplines (e.g., neurosurgery, neuropathology, neurology, medical oncology etc.) and 33 
decides together on the use of the tissue specimens. A critical step is the proper processing 34 
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and characterization (e.g., with respect to representativeness and tumor cell content) of 1 
surgical tissue specimens prior to banking, which requires expert neuropathological input, 2 
particularly from neuropathologists interested in research applications. If research-orientated 3 
neuro-oncologists and neurosurgeons then complement clinical information and other 4 
additional features (such as patient blood samples), tissue banks become a valuable resource. 5 
These resources become potentially yet more valuable if materials and information can be 6 
shared in inter-institutional ways, for example to support large trials or large genomic studies. 7 
Thus, tumor banks by linking clinical and basic research are an integral part of our 8 




Argument #2: Clinical care is necessarily complex and needs expert neurooncologists 13 
 14 
#2a: Molecular markers increasingly influence therapy decisions 15 
In addition to aiding in diagnosis and classification, molecular markers are now also affecting 16 
therapeutic decisions. The prognostic or therapy-predictive role of these markers has been 17 
partly clarified within clinical trials. To date, a number of adequately powered phase III- or 18 
randomized phase II-clinical trials have been performed or are enrolling. These trials may 19 
change the standards for the treatment of high-grade gliomas on basis of molecular 20 
evaluations (Table 2). Therefore, molecular markers, particularly in high-grade tumors, will 21 
gain an increasing role for therapy stratification, make therapeutic decisions more individual 22 
and thus necessitate a close dialogue between clinicians and neuropathologists. This is not 23 
only true for medical neurooncologists, but also for neurosurgeons, radiotherapists and 24 
diagnostic disciplines as neuroradiology.  25 
In the following we provide examples on how molecular information supports current 26 
therapeutic decisions in glioblastomas and anaplastic gliomas: 27 
 28 
 Clinical impact of molecular markers in glioblastomas 29 
The EORTC 26981/22981 NCI-C3.0 trial demonstrated the relevance of MGMT 30 
promoter methylation in glioblastomas by comparing treatment with temozolomide 31 
radio-chemotherapy with radiotherapy only [52, 131]. In this trial, methylation was 32 
predictive for benefit from chemo- and radiotherapy, a result that was later verified in 33 
the phase III RTOG 0525 trial [1]. Results from the EORTC 26891 combined treatment 34 
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arm are often used as standard arm in trial design, and still, there has been no fully 1 
published trial that shows better results. RTOG 0525 failed to show that an intense 2 
regimen of temozolomide is more effective than the standard regimen either in patients 3 
with glioblastoma with a methylated or unmethylated MGMT promoter [1]. However, as 4 
there is no approved alternative to radio-chemotherapy with temozolomide at this time, 5 
the predictive value of the MGMT promoter methylation does not lead to a stratified 6 
treatment of patients with glioblastoma. This is different in elderly patients with 7 
glioblastoma above an age of 65: efficacy of temozolomide as a monotherapy in older 8 
patients was verified in the Nordic trial [82] and the german randomised phase 3 NOA-9 
08 trial; as shown by NOA-08, dose-dense temozolomide and radiotherapy in a 10 
conventional fractionation scheme are generally equally effective [149]. However, 11 
patients with MGMT promoter methylation have an increased overall survival under 12 
temozolomide monotherapy. Therefore, these patients should be treated with 13 
chemotherapy, whereas patients without MGMT promoter methylation or with an 14 
unknown MGMT status should be treated with radiotherapy. Finally, data that 15 
bevacizumab increases PFS from around 6 to 10 months [26] and possible approval of 16 
bevacizumab may lead to a shift in the first-line treatment of glioblastomas, leading to 17 
bevacizumab treatment in patients with an unmethylated MGMT promoter (see #2b, 18 
below). 19 
 20 
 Clinical impact of molecular markers in anaplastic gliomas  21 
In the german NOA-04 trial for anaplastic astrocytomas and anaplastic oligodendroglial 22 
tumors, hypermethylation of the MGMT promoter, mutation of IDH1 and 23 
oligodendroglial histology were verified as favorable prognostic markers [148]. 24 
However, MGMT promoter methylation was not predictive for a benefit from 25 
chemotherapy. Other publications substantiate the prognostic value of molecular 26 
markers in grade III gliomas [137]. In addition, data from two studies on WHO grade III 27 
oligodendroglial tumors [20, 138] recently showed that the overall survival of patients 28 
with a combined loss of 1p and 19q doubles from approximately 7 to about 14 years if 29 
combined treatment with radiotherapy and chemotherapy with procarbazine, CCNU and 30 
vincristine (PCV) is used. Even if these data were evaluated retrospectively, they appear 31 
so convincing that a paradigmatic change in the treatment of these patients may result; 32 
in contrast, patients without 1p/19q loss will most likely be treated with radiotherapy, 33 
temozolomide or PCV as a monotherapy.  34 
10 
 
Most of the classical molecular markers have not been prospectively verified in independent 1 
trials. In the EORTC 26981/22981 NCI-C3.0 trial, for example, MGMT promoter methylation 2 
was evaluated post hoc in a subset of 206 of 573 treated patients. The evaluation of fewer than 3 
half of the specimens, with the rest of specimens not being available or investigable, may 4 
have introduced a statistical bias. Even in later trials with a prospective evaluation of MGMT 5 
methylation, the rate of evaluated specimen has been in the range of 50-60% [1, 148]. Also, 6 
the situations discussed above do not offer a stratified therapeutic approach for all patients 7 
with high-grade gliomas, with the situation being even less clear in WHO grade II glioma 8 
patients.  9 
 10 
In such instances, crosstalk between tissue and imaging diagnostic disciplines also comes into 11 
play and is essential to guide neurosurgery, radiotherapy and treatment response assessment. 12 
Therapeutic disciplines increasingly rely on functional and metabolic imaging to guide 13 
diagnostics and treatment [2]. For example, neurosurgeons use functional and biological 14 
imaging to increase the extent of resection or to guide biopsy of the anaplastic focus of diffuse 15 
tumors [40, 96, 145]. However, diagnosis and evaluation of response phenomena such as 16 
pseudoprogression and pseudoresponse cannot be solely based on imaging methods, such as 17 
MRI and PET [35, 86, 151], as the rate of false positive or negative imaging results is still 18 
considerably high. Radiotherapists increasingly plan treatment along the biological tumor 19 
volume that is evaluated by positron emission tomography [100, 144], and a value for 20 
magnetic resonance spectroscopy has been suggested [39]. In this situation, correlation of the 21 
biological tumor volume to histopathological and molecular features will be helpful to verify 22 
this apporach.  23 
 24 
No single reliable tumor marker has yet been detected for gliomas and serum markers for 25 
glioma diagnosis are not available at the present time. Nonetheless, in regard to a potential 26 
serum markers for monitoring tumor load or tumor progression, small molecules such as 27 
miRNAs might bear promising diagnostic perspectives [57]. Thus, additional controlled 28 
studies involving proper histological and molecular work-up and development of novel 29 
imaging and serum markers are needed.  30 
 31 
Regardless of the modalities involved, the number of different technologies and the nuances 32 
inherent in understanding the evidence levels offered by such approaches, it is clear that 33 
11 
 
treatment decisions for such patients are best discussed in multidisciplinary tumor boards that 1 
include experts well aware of the strengths and weaknesses of all of these technologies.  2 
 3 
 4 
#2b: Targeted agents provide therapeutic options beyond standard alkylating chemotherapy    5 
The current goal of many areas of oncology is the development of innovative targeted 6 
therapies. Achieving effective targeted approaches will require close interaction between 7 
basic scientists and clinicians, as well as a developmental pipeline from basic to translational 8 
to clinical research. Most of these approaches are still at an experimental stage and most are 9 
therefore introduced later in this review (see #4a below).  10 
 11 
The currently most advanced example of a therapeutic strategy beyond standard alkylating 12 
agents is the selective blockade of pro-angiogenic pathways with the humanized monoclonal 13 
antibody bevacizumab [62, 101]. By binding the VEGF-A ligand, bevacizumab inhibits the 14 
receptor-ligand interaction [66, 129]. Bevacizumab has been used as a monotherapy or in 15 
combination with chemotherapeutic agents as irinotecan or temozolomide. In the first phase II 16 
trials in relapse of high-grade gliomas, high response rates of up to 63%, a significant increase 17 
of progression free survival (PFS) at 6 months (38%), and a small increase of overall survival 18 
have been shown in comparison to historical data [142] - observations that however could not 19 
be fully substantiated in subsequent trials. In most trials, response rates of about 30% have 20 
been reported. Bevacizumab has been preliminarily approved by the FDA for the treatment of 21 
relapsing or progressive high-grade gliomas [43], and several alternative regimens have been 22 
tested using bevacizumab as monotherapy or combined with other cytotoxic agents, i.e., 23 
irinotecan, temozolomide or nitrosourea. A trial of the EORTC focusing on the sequential 24 
therapy of patients with first relapse of glioblastoma (EORTC 26101) using bevacizumab and 25 
CCNU in several combinations is enrolling patients at this time and additional controlled 26 
studies involving proper histological, molecular and imaging work-up are urgently needed to 27 
identify those patients that are most likely to benefit.  28 
 29 
In addition to the use of bevacizumab in relapse, two first-line phase III trials have been 30 
initiated that have shown early promising results of a significant increase of PFS in 31 
glioblastoma [26]. The difference in OS was not significant at the time of presentation, 32 
suggesting that bevacizumab may only prolong the clinically relevant first phase of the 33 
disease until first progression. As such, an improved understanding of the side-effects of 34 
12 
 
targeted agents appears necessary. Antiangiogenic therapy has been shown to increase the 1 
invasive properties of glioma cells. Early in vitro data [73] have recently been challenged by 2 
observations from human high-grade glioma trials using bevacizumab, where an increased 3 
FLAIR-enhancement suggesting increased invasion has been observed using magnetic 4 
resonance imaging (MRI) [3, 102]. However, other investigators could not reproduce these 5 
results [147]. These multidisciplinary results from both basic research as well as clinical 6 
studies raise the question if a combined use of anti-angiogenic and anti-invasive drugs may be 7 
advantageous and warrant careful evaluation of clinical and imaging response as well as 8 




Argument #3: Basic research is needed to drive translational research 13 
The development of novel anticancer therapies is a major goal in neurooncology, yet progress 14 
in this direction is still moderate. Since many substances fail in controlled clinical trials, the 15 
costs for the substances that reach market approval are tremendously high. Thus, less 16 
fragmented and instead more streamlined and cost-effective research approaches are needed. 17 
Translational research is a promising way to bridge basic and clinical research. There is a 18 
growing awareness of the fact that basic scientists on the one hand should provide input into 19 
the development of clinical trials and that pre-clinical research projects would benefit from 20 
the input of clinicians. Molecular aspects have to be better incorporated into clinical studies 21 
and clinical demands have to be considered for defining relevant basic research projects. A 22 
translational research pipeline that turns basic scientific discoveries into clinicial applications 23 
is a long and multistep process that requires a committed dialogue between experts from 24 
multiple disciplines. It will also be enriched by qualified individuals with medical and 25 
laboratory-based knowledge (so-called physician scientists). In our conceptional framework 26 
academically-based brain tumor centers that harbor both clinical and basic research 27 
disciplines are therefore ideally suited for addressing this task (Fig. 1). 28 
 29 
 30 
 #3a: Deeper insights into tumor biology are needed to identify novel promising targets of 31 
clinical use 32 
Innovative treatment approaches necessarily require insights into the molecular basis of the 33 
disease. Over the past twenty years, tremendous progress has been made in unveiling the 34 
13 
 
different pathophysiological events contributing to gliomagenesis and glioma progression. 1 
Indeed, “glioma” is a heterogenous group of diseases, and the subsequent hope is that the 2 
different molecular events could be targeted by distinct treatment approaches. Processes may 3 
be targeted, for example angiogenesis or tumor cell proliferation. Experimental data from in 4 
situ analyses and microdissected glioma cell populations from different tumor regions 5 
suggest, for example, that infiltrating glioma cells contain unique molecular profiles [33, 84] 6 
and some of these differentially activated molecules and pathways could serve as targets for 7 
therapies aiming at reduction of the infiltrative nature of the disease: among others, the 8 
dysregulation of EGFR and integrin signaling pathways could affect the tumor infiltration 9 
zone [74, 95, 116].  10 
 11 
Recent studies have raised the possibility that tumor-initiating cells such as cancer stem cells 12 
may be the most relevant targets for successful therapies [9, 12, 141]. The hypoxic niche is 13 
appreciated as a major relevant local factor for the growth and propagation of glioma stem 14 
cells [128]. In this regard, targeting the vascular components of the niche can lead to 15 
eradication of brain tumor initiating cells (BTICs) [42, 55]. Interestingly in this context, the 16 
expression of C/EBPbeta (one of the master regulators of the mesenchymal expression 17 
signature; see below) is closely associated with areas of necrosis, i.e., areas of intratumoral 18 
hypoxia [28]. Thus, targeting tumor cells with a hypoxia-tag may be particularly promising in 19 
eradicating those cell populations that sustain tumor growth and regrowth. Nevertheless, the 20 
definition and identification of tumor-initiating cell populations has to be refined to enable 21 
potential novel stem-cell directed therapeutic approaches.  22 
 23 
While the above studies suggest the possibility of reasonable targets, this is only the first part 24 
in a long experimental pipeline for the development of successful clinical therapies. 25 
Experimental findings derived from cell culture and animal models have to be verified for 26 
their relevance to the human in vivo situation. Novel potential target molecules should be 27 
loaded with clinical prognostic and predictive information. As such, close interfaces between 28 
basic scientists and clinicians are essential to drive the development of these basic research 29 
insights into practical clinical applications and will require a multidisciplinary and 30 





#3b: Molecular alterations have to be put into a meaningful context to extract those 1 
molecular changes that really matter 2 
While many individual molecules could be targeted, approaches directed against single 3 
molecules have failed to date (see below, #4a). One reason for such failure may be that the 4 
tumor does not depend on the specific targeted molecular alteration, given the complexity of 5 
intracellular signaling relationships. Multiple alternative upstream alterations may lead to the 6 
dysregulation of identical downstream signaling intermediates in pathways [113, 116]. The 7 
situation becomes even more complex due to intratumoral heterogeneity and because multiple 8 
levels of molecular regulation affect one another (Fig. 2). In addition to genomic alterations 9 
(such as mutations or gene amplification), RNA and protein alterations contribute to a 10 
molecular make-up of the tumor. Epigenetic regulation superimposes an additional regulatory 11 
layer, with not only gene methylation and histone modifications but also miRNAs regulating 12 
complex networks of cancer genes. These signaling relationships have to be kept in mind 13 
when designing targeted therapeutic approaches and basic research can therefore best drive 14 
translational research by putting genes into context.  15 
 16 
In 2008, The Cancer Genome Atlas (TCGA) reported an integrative analysis of DNA copy 17 
number, gene expression and DNA methylation profiling in a collection of 206 human 18 
glioblastomas [22]. This study confirmed the multitude of molecular aberrations that had been 19 
previously identified by individual researchers but also highlighted three signaling pathways 20 
of major importance in the broad majority of these tumors: CDK/cyclin/CDK inhibitor/pRB, 21 
p53, and RTK/RAS/PI3K (Fig. 3). A second approach substantiated these major molecular 22 
pathways defining glioblastomas [98]. These common pathways may serve to provide central 23 
targets to target the disease efficiently.  24 
 25 
As mentioned above, global molecular approaches may also identify novel prognostic 26 
subclasses of high-grade astrocytomas: proneural, proliferative and mesenchymal expression 27 
patterns [11, 28, 75, 99, 140]. While tumors from the proneural subclass are highly enriched 28 
for neuronal lineage markers and exhibit better survival, proliferative and mesenchymal tumor 29 
subclasses are enriched for neuronal stem cell markers and display shorter survival. Upon 30 
recurrence, a frequent shift in expression patterns towards the mesenchymal subclass has been 31 
observed. Of note, two transcription factors (C/EBPbeta and STAT3) have been suggested as 32 
master regulators that could control the transition into a prognostically unfavorable gene 33 
expression profile [23]. Experimentally, the ectopic co-expression of C/EBPbeta and STAT3 34 
15 
 
reprogrammed neural stem cells along the aberrant mesenchymal lineage, while elimination 1 
of the two factors in glioma cells resulted in a loss of the mesenchymal signature and a 2 
reduction of tumour aggressiveness. Given that a hierarchy with a concerted regulation of 3 
multiple molecules exists and that a shift of whole expression patterns can be induced by 4 
single molecules, C/EBPbeta and STAT3 could be priority targets for therapeutic 5 
intervention.  6 
 7 
In addition, meaningful molecular signatures may not only be restricted to the transcriptional 8 
level. For example, the TCGA highlighted a distinct subset of samples that had concerted 9 
hypermethylation at a large number of loci, indicating the existence of a glioma-CpG island 10 
methylator phenotype (G-CIMP) [92]. This hypermethylation signature overlapped with the 11 
proneuronal expression signature described above, and was more prevalent among lower-12 
grade gliomas and associated with a significantly improved outcome. More recently, 13 
additional subgroups of glioblastoma with distinct global methylation patterns have been 14 
suggested defined by H3F3A mutations affecting two critical amino acids (K27 and G34) of 15 
histone H3.3 [132], and others have subgrouped glioblastomas according to miRNA 16 
expression profiles [67, 105] or histone modification patterns [80]. 17 
 18 
These findings indicate that biological knowledge of glioma biology is becoming increasingly 19 
complex and that advanced bioinformatic methods are needed to allow cross-platform 20 
correlations for extracting those molecular changes that are most meaningful in a clinical 21 
context. Basic and translational scientists as well as bioinformaticians need to be included in 22 
multidisciplinary research-orientated brain tumor teams. While not directly involved in 23 
clinical patient care, they can well contribute innovative impulses by identifying promising 24 




Argument #4: Translational research is needed to drive clinical research 29 
 30 
“From bench to bedside” is a goal occasionally envisaged in ambitiuous research grant 31 
proposals. As obvious from the examples provided above, basic tumor-biology orientated 32 
research approaches may be distant from clinical applications and benefit from the input of 33 
clinically orientated researchers in order to be catalyzed into practical patient care. On the 34 
16 
 
other hand, since basic research is necessarily more speculative and hypothesis-driven it may 1 
therefore - in the long run - lead to more fundamental breaktroughs and more radical 2 
paradigm shifts in practice than would clinical research alone. As such clinical research 3 
depends on basic research input to ask the most innovative questions, leave well-trodden trails 4 
and thereby accelerate therapeutic advancements.   5 
 6 
 7 
#4a: Clinical studies are needed that are based on attractive molecular targets derived from 8 
basic research approaches    9 
Translational research requires the transfer of basic scientific findings into clinical 10 
applications. Earlier in this review we introduced bevacizumab as the currently most 11 
advanced targeting agent that supplements therapeutic options in glioma care. In addition, 12 
other promising molecular targets have been or are currently being tested in early clinical 13 
trials. The most important of these are summarized in the following section. 14 
 15 
 Antiangiogenic agents other than bevacizumab 16 
In addition to bevacizumab, several small molecule tyrosine kinase inhibitors as 17 
sunitinib [91, 97], sorafenib [34, 90], cediranib [7, 8], pazopanib [60], vatalanib [14, 18 
107] and vandetanib [36, 70] have anti-angiogenic properties (Fig. 3). The molecular 19 
mechanism of these agents is similar in that each binds angiogenesis-relevant receptor 20 
tyrosine kinases or intracellular signaling molecules and therefore inhibits angiogenic 21 
signaling pathways. Inhibiting multiple targets at once may overcome the redundancy of 22 
intracellular signaling pathways. Suprisingly, none of the mentioned antiangiogenic 23 
agents except bevacizumab has been effective in clinical studies. Cediranib showed 24 
significant efficacy in an animal model and promising results in an early phase I/II 25 
clinical trial and therefore entered phase III in newly diagnosed glioblastoma, based on 26 
a strong drug development pathway of the respective company [6, 8, 61]. However, it 27 
then failed, leading to the assumption that it might be more promising to inhibit the 28 
ligand rather than the receptor or signaling cascade of antiangiogenic pathways.  29 
 30 
 Targeting the integrin cell adhesion receptor family  31 
The alphaV-beta3 and alphaV-beta5 integrin receptors are expressed in glioma and 32 
tumor endothelial cells [24], contribute to tumor angiogenesis and migration, and may 33 
thus constitute promising targets for specific approaches. Cilengitide is a selective 34 
17 
 
inhibitor of integrins on endothelial cells with a predominant antiangiogenic effect, but 1 
has a bimodal biological effect since it also shows anti-invasive properties on tumor 2 
cells [124]. The inhibitor was investigated in several clinical protocols [87, 109, 110, 3 
111, 130] and a promising median PFS of 8 months and 12- and 24-month overall 4 
survival rates of 68% and 35% have been reported in first-line therapy [130], especially 5 
for patients whose tumors have a methylated MGMT promoter. These clinical data led 6 
to the initiation of a large registration trial for patients in the primary therapy of 7 
glioblastoma with MGMT promoter metylation (CENTRIC; [133]) and a smaller phase 8 
II trial for patients whose tumors have non-methylated MGMT. Results were recently 9 
communicated in a press release by Merck; there was no benefit for the combination of 10 
radiochemotherapy with cilengitide in comparison to radiochemotherapy alone. 11 
 12 
 Tyrosine kinase receptor inhibition  13 
EGFR is amplified or overexpressed in its truncated form (EGFRvIII) in many 14 
glioblastomas, inducing excess kinase activity [115]. However, EGFR kinase inhibitors 15 
such as gefitinib, erlotinib and lapatinib have been unsuccessful in clinical trials [29, 16 
103, 152]. Successful treatment has been claimed for some patients with coexpression 17 
of EGFRvIII and PTEN [89], but this has not been confirmed in subsequent studies. 18 
Recently, a investigational immunotherapeutic vaccine that targets the tumor-specific 19 
EGFRvIII has been developed and is currently being investigated in the international 20 
phase II and III ACT IV trial [31, 32].  21 
PDGFR is another attractive target for the treatment of high-grade gliomas given the 22 
presence of PDGFR amplification/overexpression in many of these tumors [115]. The 23 
small molecule inhibitor imatinib mesylate was developed in the 1990s and is a ground 24 
breaking targeted agent that shows an over 90% response rate in chronic myeloid 25 
leukemia [37, 38]. Following the publication of first results from these trials, imatinib 26 
was investigated in a number of solid tumors. However, after promising early results 27 
[108], a phase III registration trial in high-grade gliomas was negative [106], illustrating 28 
that tumors that do not depend on a single driver oncogene will likely not respond to 29 
such therapeutic approaches.  30 
 31 
 Other targeted approaches  32 
Inhibitors of protein kinase Cß [15, 16, 69, 104, 150], PI3K/Akt/mTor inhibitors [25, 33 
44, 123] and inhibitors of other receptor kinase or intracellular targets (e.g. notch, SHH, 34 
18 
 
histone deacetylase) have been investigated in phase II or early phase I trials and have 1 
failed, despite promising laboratory and animal data. In terms of immunmodulatory 2 
therapies, TGF-ß2 targeted antibodies, antisense oligonucleotides or small molecule 3 
inhibitors are the most advanced in clinical application [48, 49, 50, 126, 127], but their 4 
efficacy remains unclear at this time. 5 
 6 
Most investigated targeted agents, therefore, have been unsuccessful to date in clinical phase 7 
II and III trials. This raises the question of why these biologically compelling molecules did 8 
not turn out to be clinically effective. The most ready explanation for such failure is that 9 
agents targeting a single molecule may not be sufficient to tackle the highly complex 10 
molecular oncogenic backbone of glioblastomas. Instead, multitargeted approaches may 11 
constitute an attractive and improved option and, as a result, first attempts in this direction 12 
have been made by using multi-target inhibitors as sorafenib [34, 90], cediranib [13] and 13 
sunitinib (against VEGFR1-3, PDGFR-a/b, FLT-3, c-KIT and RET) [91, 97] or combinations 14 
of cilengitide plus temozolomide [130]), EGFR-targeted vaccination and temozolomide [53], 15 
or bevacizumab plus irinotecan (Genentech trial; [43]).  16 
 17 
 18 
#4b: Mechanisms of therapy failure and resistance have to be understood to improve 19 
therapeutic regimens 20 
 21 
Most glioblastoma patients receive intensive neurooncological postsurgical care and are 22 
included into controlled clinical trials or are treated with standard radiochemotherapy using 23 
concomitant and adjuvant temozolomide [131]. Thus, the issue of chemotherapy resistence or 24 
failure becomes more important in terms of improving therapeutic regimens. Major 25 
preexisting tumor-intrinsic reasons for low efficacy of chemo- and targeted therapy against 26 
glioblastoma are poor blood-brain barrier penetration of cytostatic agents (especially in the 27 
therapeutically relevant periphery of the tumor) [46], expression of drug efflux pumps 28 
(multidrug resistance genes) [30, 63, 79], and the expression of resistance-associated proteins 29 
such as MGMT [51]. However, because of genetic instability and clonal selection, tumor cells 30 
may also develop molecular escape mechanisms under therapy that counteract the benefical 31 




In a recent study by the German Glioma Network, pairs of primary and recurrent tumors from 1 
64 glioblastoma patients treated with radiotherapy and TMZ were investigated, revealing 2 
significantly lower expression levels of the mismatch repair genes MSH2, MSH6 and PMS2 3 
but no relevant changes in MGMT promoter hypermethylation [134]. Indeed, MSH6 in this 4 
context appears to be a relevant player. A large-scale sequencing screen of the functional 5 
domains of 518 protein kinases identified inactivating somatic mutations of the mismatch 6 
repair gene MSH6 in two gliomas that had recurred after treatment with alkylating agents [58] 7 
and sequencing of MSH6  in 46 clinically well-characterized glioblastomas revealed that the 8 
frequency of MSH6 mutations was significantly increased in recurrent glioblastomas [17]. 9 
These data suggest that MSH6 deficiency (and maybe also the deficiency of other mismatch 10 
repair genes) may contribute to recurrences during maintenance treatment and that patients 11 
who initially responded to a frontline therapy may evolve treatment resistance by developing 12 
a hypermutator phenotype [153]. Further in vitro data indicated that through exposure of an 13 
MSH6 wild-type glioblastoma line to temozolomide resistant clones evolved with one of them 14 
harboring an MSH6 mutation [22]. Also, knockdown of MSH6 in the U251 glioblastoma cell 15 
line increased resistance to temozolomide cytotoxicity and its reconstitution restored 16 
cytotoxicity in MSH6-null glioma cells. It is hoped that  better understanding of the biological 17 
mechanisms by which tumor cells escape the response to chemotherapy may be utilized to 18 
develop novel strategies to overcome or at least minimize chemotherapy resistance; for 19 
example, with respect to MSH6, a possible approach would be an upfront combination of 20 
alkylating agents with selective agents targeting mismatch-repair-deficient cells.  21 
 22 
Further studies are needed to extend these observations, including to the epigenetic level. For 23 
example, in temozolomide resistant glioma cells, LINE-1 methylation, an indicator of global 24 
DNA-methylation and a positive prognostic factor in gliomas, is reduced [45, 94]. This could 25 
suggest that a lower global DNA methylation impairs DNA stability and activates novel 26 
chemotherapy resistance. Based on the knowledge about molecular markers for early response 27 
and resistance, adaptive clinical trials could be designed that would better overcome the 28 










The approaches described above, within or outside clinical trials, can only be coordinated at 3 
dedicated brain tumor centers. A number of such centers have been founded within the last 4 
decades, starting from the US and now reaching Europe and Asia. Such centers typically 5 
include departments of neurosurgery, radiation ooncology, neurology and medical oncology, 6 
and specialized diagnostic units for neuropathology and neuroradiology. Our experiences 7 
working in such environments suggest that the individual patient case must be coordinated 8 
prospectively (including discussions on diagnostics and treatment planning) to meet the goals 9 
of quick decision making and structured, tailored treatment. We would argue further that a 10 
strong agenda combining translational development of new treatment approaches with the 11 
performance of clinical trials is best suited to serve patients both within clinical trials and also 12 
on an individual basis.  13 
 14 
Equally important is a close connection of brain tumor centers with local institutions and 15 
community-based physicians. Such connectivity is essential to make local treatment possible, 16 
especially with regard to supportive treatments and management of complications. Local 17 
medical centers in this regard assume an important role in our conceptional framework of 18 
multidisciplinary and multiinstitutional brain tumor management (Fig. 1). Expertise can be 19 
brought to local centers by use of electronically connected consults and tumor boards. In such 20 
cooperative networks, local medical centers would be able to incorporate expertise from 21 
highly specialized disciplines, such as neuropathology and neuroradiology that might not be 22 
locally availaible. Bringing cutting edge diagnostics and treatment "close to home" is an 23 
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Tables and figure legends 1 
 2 
Table 1. Molecular markers with diagnostic relevance. 3 
IDH1/2 
mutation 
glioblastoma: genetically either primary (IDH wildtype) or secondary (IDH mutated) 
glioblastoma    
high-grade glioma with overtly anaplastic histology lacking necrosis and not fulfilling 
all histological criteria for the diagnosis of glioblastoma: lack of IDH mutations might 
point to a tumor that behaves like a glioblastoma 
gliosis versus glioma: detection of invading tumor cells by the presence of a mutation 
increases the sensitivity of glioma diagnostics 
1p/19q 
deletion 
tumors with borderline oligodendroglial features: detection of the 1p/19q codeletion 
may reflect a prognostically favorable oligodendroglioma diagnosis 
oligoastrocytoma: may guide consideration as oligodendroglial (1p/19q deleted) or 
astrocytic in nature (1p/19q retained, TP53 mutated). 
BRAF 
alterations  
BRAF-KIAA1549 fusion: presence conistent with pilocytic astrocytoma rather than a 
diffusely infiltrative astrocytoma (particularly when tested in tandem with IDH1 and 
IDH1 not mutated). 
BRAF V600E mutation: for differentiation of pleomorphic xanthoastrocytoma, 
gangliogliomas and extra-cerebellar pilocytic astrocytomas (frequent BRAF V600E 
mutation) from diffusely infiltrating astrocytic gliomas (rare BRAF V600E mutation).  
 4 
 5 
Table 2. Ongoing or recently closed phase III clinical trials in adult patients with first line or 6 
relapsed glioblastoma, based on a search in ClinicalTrials.gov. All listed trials are recruiting 7 
or have not published results yet, except abstracts at scientific meetings. Only trials from 8 
major study groups and industry are listed. AvaGlio in abstract form has reported a PFS of 6.2 9 
months for the standard arm and 10.6 months for the experimental arm (p<0,0001).  10 
Treatment Short name Disease No. of Pat. Endpoint Mol. selection Primary study group / company Trial identifier 
Bevacizumab + TMZ/RT vs. TMZ/RT  RTOG 0825 GBM, first-line  942  PFS, OS  no RTOG NCT00884741 
Bevacizumab + TMZ/RT vs. TMZ/RT  AvaGlio GBM, first-line 920  PFS, OS  no Roche NCT00943826 
Cilengitide + TMZ/RT vs. TMZ/RT  CENTRIC GBM, first-line 504  OS  yes (MGMT) EORTC / Merck NCT00689221 
NovoTTF-100A + TMZ/RT vs. TMZ/RT - GBM, first-line 700 PFS no NovoCure NCT00916409 
Rindopepimut + GM-CSF vs. TMZ/RT  ACT IV GBM, first-line 440 OS yes (EGFRvIII) Celldex NCT01480479 




Figure 1. Conceptional framework of an optimized multidisciplinary brain tumor 1 
management as proposed in this review article. Affiliation of brain tumor patients to 2 
academically-based brain tumor centers guarantees state-of-the art treatment and enables 3 
access to innovate research-driven clinical approaches. Collaborative clinical networks 4 
convey expertise from brain tumor to local medical centers and allow for supportive treatment 5 
and management of complications “close to home” in a socially embedded environment. 6 
 7 
Figure 2. Illustration of the layers of histological and molecular information that coexist 8 
within a patient’s diagnostic tumor sample. Typing and grading based on the histological 9 
classification represent the basis for the estimation of the tumors biological behavior. 10 
Histological diagnosis may be supplemented by molecular information on a multitude of 11 
genes, molecular markers or complex gene signatures. This molecular information is 12 
represented on different molecular levels (epigenetic, genomic, transcriptional) or in different 13 
areas of the tumor microstructure (e.g. tumor center vs. tumor border), but highly mutually 14 
interconnected: IDH mutations, e.g., might lead to global epigenetic changes and miRNAs 15 
regulate complex transcriptional networks. Nevertheless, the multitude of single molecular 16 
alterations converges into a manageable number of common signaling pathways. As such a 17 
context-dependent interpretation of individual molecular changes appears helpful for 18 
developing efficient targeted therapeutic strategies.  19 
 20 
Figure 3. Candidate mechanisms and molecules for targeted therapies. A multitude of single 21 
molecular alterations converge into relatively common signaling pathways that are highly 22 
interconnected and that may be targeted by available agents. Features of tumor and 23 
endothelial cells have been combined in this figure and angiogenic pathways, which are 24 
clinically most relevant at this time, are overrepresented. 25 
 26 
 27 
